Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

Fertility and Sterility

Volumn 81, Issue 1, 2004, Pages 19-25

  Fauser, Bart C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE; TRIACYLGLYCEROL;

ANOVULATION; BIOCHEMISTRY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FAMILY STUDY; GLUCOSE TOLERANCE TEST; HEALTH CARE ORGANIZATION; HEALTH HAZARD; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL IRREGULARITY; MORPHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM; THYROID DISEASE;

EID: 0346725827     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.10.004     Document Type: Article

References (95)

1. Zawadski J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome towards a rational approach . Dunaif A., Givens J.R., Haseltine F. Polycystic ovary syndrome. 1992;377-384 Blackwell Scientific, Boston.
2. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 338:1998;1876-1880.
3. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome a multicenter, double blind, placebo-controlled trial . J Clin Endocrinol Metab. 86:2001;1626-1632.
4. Chang R.J., Katz S.E. Diagnosis of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 28:1999;397-408.
5. Laven J.S., Imani B., Eijkemans M.J., Fauser B.C. New approaches to PCOS and other forms of anovulation. Obstet Gynecol Surv. 57:2002;755-767.
6. Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome a prospective, controlled study in 254 affected women . J Clin Endocrinol Metab. 84:1999;165-169.
7. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 22:1999;141-146.
8. Adams J., Polson D.W., Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J. 293:1986;355-359.
9. Franks S. Polycystic ovary syndrome a changing perspective (review) . Clin Endocrinol. 31:1989;87-120.
10. Carmina E., Lobo R.A. Polycystic ovaries in hirsute women with normal menses. Am J Med. 111:2001;602-606.
11. Dunaif A., Graf M., Mandeli J., Laumas V., Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:1987;499-507.
12. Robinson S., Kiddy D., Gelding S.V., Willis D., Niththyananthan R., Bush A., et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol. 39:1993;351-355.
13. Carey A.H., Chan K.L., Short F., White D., Williamson R., Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol. 38:1993;653-658.
14. Legro R.S., Driscoll D., Strauss J.F. III, Fox J., Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 95:1998;14956-14960.
15. Azziz R., Hincapie L.A., Knochenhauer E.S., Dewailly D., Fox L., Boots L.R. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women a prospective study . Fertil Steril. 72:1999;915-925.
16. Anovulatory infertility. Hum Reprod. 10:1995;1549-1553.
17. Rowe PJ, Comhaire FH, Hargreave TB. Female partner. In: World Health Organization manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press, 2000:40-67.
18. Van Santbrink E.J., Hop W.C., Fauser B.C. Classification of normogonadotropin infertility polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of PCOS . Fertil Steril. 67:1997;452-458.
19. Moller D.E., Cohen O., Yamaguchi Y., Azziz R., Grigorescu F., Eberle A., et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes. 43:1994;247-255.
20. Kreisberg R.A. Clinical problem-solving. Half a loaf. N Engl J Med. 330:1994;1295-1299.
21. Waggoner W., Boots L.R., Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms a populational study . Gynecol Endocrinol. 13:1999;394-400.
22. Pache T.D., Chadha S., Gooren L.J., Hop W.C., Jaarsma K.W., Dommerholt H.B., et al. Ovarian morphology in long-term androgen-treated female-to-male transsexuals. A human model for the study of PCOS? Histopathology. 19:1991;445-452.
23. Diamanti-Kandarakis E., Koulie C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., et al. A survey of the polycystic ovary syndrome in the Greek Island of Lesbos a hormonal and metabolic profile . J Clin Endocrinol Metab. 84:1999;4006-4011.
24. Carmina E., Koyama T., Chang L., Stanczyk F.Z., Lobo R.A. Does ethnicity influence the prevalence of adrenal hyperandrogenism in insulin resistance in the polycystic ovary syndrome? Am J Obstet Gynecol. 167:1992;1807-1812.
25. Ruutiainen K., Erkkola R., Gronroos M.A., Irjala K. Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages. Fertil Steril. 50:1998;260-265.
26. Slayden S.M., Moran C., Sams W.M. Jr, Boots L.R., Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil Steril. 75:2001;889-892.
27. Futterweit W., Dunaif A., Yeh C., Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Med Acad Dermatol. 19:1988;831-836.
28. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women in the Southeastern United States a prospective study . J Clin Endocrinol Metab. 83:1988;3078-3082.
29. Pugeat M., Nicolas M.H., Craves J.C., Alvarado-Dubost C., Fimbel S., Cechaud H., et al. Androgens in polycystic ovarian syndrome. Ann NY Acad Sci. 687:1993;124-135.
30. Balen A.H., Conway G.S., Kaltsas G., Techatrasak K., Manning P.J., West C., et al. Polycystic ovary syndrome the spectrum of the disorder in 1741 patients . Hum Reprod. 10:1995;2107-2111.
31. Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 85:2000;2434-2438.
32. Boots L.R., Potter S., Potter H.D., Azziz R. Measurement of total serum testosterone levels using commercially available kits high degree of between-kit variability . Fertil Steril. 69:1998;286-292.
33. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab. 82:1997;2014-2015.
34. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 84:1999;3666-3672.
35. Rittmaster R.S. Androgen conjugates physiology and clinical significance . Endocrine Rev. 14:1993;121-132.
36. Bili H., Laven J., Imani B., Eijkemans M.J., Fauser B.C. Age related differences in features associated with PCOS in normogonadotrophic oligo-amenorrheic infertile women of reproductive years. Eur J Endocrinol. 145:2001;749-755.
37. Moran C., Knochenhauer E., Boots L.R., Azziz R. Adrenal androgen excess in hyperandrogenism relation to age and body mass . Fertil Steril. 71:1999;671-674.
38. Cibula D., Hill M., Starka L. The best correlation of the new index of hyperandrogenism with the grade of increased hair. Eur J Endocrinol. 143:2000;405-408.
39. Imani B., Eijkemans M.J., de Jong F.H., Payne N.N., Bouchard P., Giudice L.C., et al. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 85:2000;676-682.
40. Tremblay R.R., Dube J.Y. Plasma concentration of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception. 10:1974;599-605.
41. Meldrum D.R., Abraham G.E. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol. 53:1979;36-43.
42. Derksen J., Nagesser S.K., Meinders A.E., Haak H.R., van de Velde C.J. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 331:1994;968-973.
43. Pache T.D., Hop W.C., Wladimiroff J.W., Schipper J., Fauser B.C. How to discriminate between normal and polycystic ovaries. Radiol. 17:1992;589-593.
44. Jonard S., Robert Y., Cortet C., Decanter C., Dewailly D. Ultrasound examination of polycystic ovaries is it worth counting the follicles? Hum Reprod. 18:2003;598-603.
45. Balen A. Ovulation induction for polycystic ovary syndrome. Hum Fertil (Camb.). 3:2003;106-111.
46. Bucket W.M., Bouzayen R., Watkin K.L., Tulandi T., Tan S.L. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod. 18:2003;598-603.
47. Dewailly D., Robert Y., Helin I., Ardaens Y., Thomas P., Lemaitre L., et al. Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol. 41:1994;557-562.
48. Christensen J.T., Boldsoen J., Westergaard J.G. Ovarian volume in gynecologically healthy women using contraception or using IUD. Acta Obstet Gynecol Scand. 76:1997;784-789.
49. Dewailly D. Definition and significance of polycystic ovaries In: Hyperandrogenic states and hirsutism . Ball Clin Obstet Gynaecol. 11:1997;349-368.
50. Imani B., Eijkemans M.J., te Velde E.R., Habbema D., Fauser B.C. A nomogram to predict the probability of live birth after clomiphene citrate ovulation induction in normogonadotrophic oligoamenorrheic infertility. Fertil Steril. 77:2002;91-97.
51. Tan S.L., Child T.J. In-vitro maturation of oocytes from unstimulated polycystic ovaries. RBM Online. 4:2002;597-600.
52. McDougall M.J., Tan S.L., Jacobs H.S. IVF and the ovarian hyperstimulation syndrome. Hum Reprod. 5:1992;597-600.
53. Swanson M., Sauerbrei E.E., Cooperberg P.L. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound. 9:1981;219-222.
54. Ferrannini E., Natali A., Bell P., Cavallo-Perin P., Lalic N., Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest. 30:1997;1166-1173.
55. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174.
56. Consensus Development Conference on Insulin Resistance. Diabetes Care. 21:1998;310-314.
57. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc. 285:2001;2486-2497.
58. Bloomgarden Z.T. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care. 26:2003;1297-1303.
59. Bloomgarden Z.T. American Association of Clinical Endocrinologists consensus conference on the insulin resistance syndrome. Diabetes Care. 26:2003;933-939.
60. Norman R.J., Masters L., Milner C.R., Wang J.X., Davies M.J. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Hum Reprod. 9:2001;1995-1998.
61. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 51:2002;2796-2803.
62. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.
63. Anonymous. Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria. Lancet 1999;354:617-21.
64. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. Diabetes Care. 22:1999;920-924.
65. Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome a prospective, controlled study in 254 affected women . J Clin Endocrinol Metab. 84:1999;165-169.
66. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation . J Clin Endocrinol Metab. 85:2000;139-146.
67. Fauser B.C., Pache T.D., Lamberts S.W., Hop W.C., de Jong F.H., Dahl K.D. Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD. J Clin Endocrinol Metab. 73:1991;811-817.
68. Taylor A.E., McCourt B., Martin K., Anderson E.J., Adams J., Schoebfeld D., et al. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metab. 82:1997;2248-2256.
69. Waldstreicher J., Santoro N.F., Hall H.J.E., Filicori M., Crowley W.F. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease indirect evidence of partial gonadotroph desensitization . J Clin Endocrinol Metab. 66:1988;165-172.
70. Tarlatzis B.C., Grimbizis G., Pournaropoulos F., Bontis J., Spanos E., Mantalenakis S. The prognostic value of basal LH FSH ratio in the treatment of patients with PCOS by assisted reproduction . Hum Reprod. 10:1995;2545-2549.
71. Balen A.H., Tan S.L., McDougall J., Jacobs H.S. Miscarriage rates following IVF are increased in women with PCO and reduced pituitary desensitization with buserelin. Hum Reprod. 8:1993;959-964.
72. Gordon U.D., Harrison R.F., Hennelly B. A randomized prospective assessor-blind evaluation of LH dosage and IVF. Fertil Steril. 75:2001;324-331.
73. Mendoza C., Ruiz E., Ortega E., Cremades N., Martinez F., Bernabeu R., et al. Follicular fluid markers of oocyte developmental potential. Hum Reprod. 17:2002;1017-1022.
74. Homburg R., Levy T., Berkovitz D., Farchi J., Feldberg D., Ashkenazi J., et al. GnRH agonist reduces the miscarriage rate for pregnancies achieved in women with PCOS. Fertil Steril. 59:1993;527-531.
75. Clifford C.K., Rai R., Watson H., Franks S., Regan L. Does suppressing LH secretion reduce the miscarriage rate? Results of a randomised controlled trial. Br Med J. 312:1996;1508-1511.
76. Hughes E, Collins J, Vandekerckhove P. GnRH analogue as an adjunct to gonadotropin therapy for clomiphene resistant PCOS (Cochrane review). The Cochrane Library 2000, Oxford Update software.
77. Al-Inani H., Aboughar M., Mansour R., Serour G. Meta-analysis of recombinant versus urinary-derived FSH an update . Hum Reprod. 18:2003;305-313.
78. Mulders A.G., Eijkemans M.J., Imani B., Fauser B.C. Prediction of chances for success and complications in gonadotrophin ovulation induction in normogonadotropic anovulatory infertility. RBM Online. 7:2003;48-56.
79. Dahlgren E., Johansson S., Lindstedt G. Women with polycystic ovary syndrome wedge resected in 1956 to 1965 a long-term follow-up focusing on natural history and circulating hormones . Fertil Steril. 57:1992;505-513.
80. Wild S., Pierpoint T., McKeigue P., Jacobs H.S. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up a retrospective cohort study . Clin Endocrinol. 52:2000;595-600.
81. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction - evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand. 71:1992;599-604.
82. Conway G.S., Agrawal R., Betteridge D.J., Jacobs H.S. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol. 37:1992;119-125.
83. Robinson S., Henderson A.D., Gelding S.V. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol. 44:1996;277-284.
84. Talbott E., Clerici A., Berga S.L. Adverse lipid and coronary heart risk profiles in young women with polycystic ovary syndrome results of a case-control study . J Clin Epidemiol. 51:1998;415-422.
85. Legro R.S., Kunselman A.R., Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 117:2001;607-613.
86. Talbott E.O., Guzick D.S., Sutton-Tyrrell K. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterio Thromb Vasc Biol. 20:2000;2414-2421.
87. Paradisi G., Steinberg H.O., Hempfling A. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 103:2001;1410-1415.
88. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy P.F. II, Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:2003;2562-2568.
89. Wild R.A. Long-term health consequences of PCOS. Hum Reprod Update. 8:2002;231-241.
90. Hardiman P., Pillay O.S., Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 361:2003;1810-1812.
91. Legro R.S. Polycystic ovary syndrome and cardiovascular disease a premature association? Endocrine Rev. 24:2003;302-312.
92. Kiddy D.S., Hamilton-Fairley D., Bush A., Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 36:1992;105-111.
93. Clark A.M., Ledger W., Galletly C. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod. 10:1995;2705-2712.
94. Huber-Buchholz M.M., Carey D.G., Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome role of insulin sensitivity and luteinizing hormone . J Clin Endocrinol Metab. 84:1999;1470-1474.
95. Moran L.J., Noakes M., Clifton P.M., Tomlinson L., Norman R.J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:2003;812-819.